Göttlicher M, Heck S, Herrlich P
Forschungszentrum Karlsruhe, Institute of Genetics, Germany.
J Mol Med (Berl). 1998 Jun;76(7):480-9. doi: 10.1007/s001090050242.
Physiological and therapeutic activities of glucocorticoids and other steroid hormones are mediated by the family of steroid hormone receptors. In addition to the classical mode of receptor action which involves binding as a dimer to regulatory sequences in target gene promoters and subsequent activation of transcription, a second mode of action is based predominantly on protein-protein interactions. As the paradigm of this so-called transcriptional cross-talk, the glucocorticoid receptor (GR) and the AP-1 transcription factor interact on target gene promoters which contain only a binding site for either one of the two transcription factors. Most frequently negative interference of both factors with each other's activity has been observed, for example, when AP-1 is composed of c-Fos and c-Jun; however, synergism is also possible under cell-specific conditions and when AP-1 is a homodimer of c-Jun. Since the detection of the GR/AP-1 cross-talk numerous other examples of transcription factor interactions have been described. Many members of the nuclear hormone receptor superfamily, including class II receptors, have been shown to participate in such cross-talk. Moreover, the transcription factor families of NF-kappaB/Rel as well as Stat, Oct, and C/EBP are engaged in cross-talk with steroid receptors. Despite the identification of a multitude of target genes which appear to be regulated by this type of transcription factor interaction, the exact molecular mechanism of the cross-talk has not yet been elucidated. This review discusses the current models to explain the molecular events of transcription factor cross-talk. Concepts are emphasized which suggest that the classical and the cross-talk mode of steroid receptor action can be triggered separately by the choice of specific ligands. A final section summarizes the partially contradictory data which assign a certain type of receptor action to a biological response particularly in the immune system.
糖皮质激素和其他甾体激素的生理及治疗活性是由甾体激素受体家族介导的。除了经典的受体作用模式,即作为二聚体与靶基因启动子中的调控序列结合并随后激活转录外,第二种作用模式主要基于蛋白质-蛋白质相互作用。作为这种所谓转录串扰的范例,糖皮质激素受体(GR)和AP-1转录因子在仅含有这两种转录因子之一结合位点的靶基因启动子上相互作用。最常见的是观察到这两种因子对彼此活性的负干扰,例如,当AP-1由c-Fos和c-Jun组成时;然而,在细胞特异性条件下以及当AP-1是c-Jun的同二聚体时,协同作用也是可能的。自从发现GR/AP-1串扰以来,已经描述了许多其他转录因子相互作用的例子。核激素受体超家族的许多成员,包括II类受体,已被证明参与这种串扰。此外,NF-κB/Rel以及Stat、Oct和C/EBP转录因子家族也与甾体受体发生串扰。尽管已经鉴定出许多似乎受这种转录因子相互作用调控的靶基因,但串扰的确切分子机制尚未阐明。本综述讨论了解释转录因子串扰分子事件的当前模型。强调了一些概念,即甾体受体作用的经典模式和串扰模式可以通过选择特定配体分别触发。最后一部分总结了部分相互矛盾的数据,这些数据将某种类型的受体作用归因于特定的生物学反应,特别是在免疫系统中。